Navigation Links
Current Hepatitis C Virus Regimens to Face Stiff Competition with the Launch of Gilead's Sofosbuvir and Janssen/Medivir's Simeprevir
Date:11/21/2013

EXTON, Pa., Nov. 21, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, following the launches of Gilead's sofosbuvir and Janssen/Medivir's simeprevir in the United States, currently marketed triple (Vertex's Incivek- and Merck's Victrelis-containing regimens) and dual therapy hepatitis C virus (HCV) regimens will lose market share to sofosbuvir-and simeprevir-based regimens. When asked about treatment practices in the next six months, surveyed physicians plan to treat 17 percent of their genotype 1 and 21 percent of their actively treated genotype 2/3 HCV patients with a sofosbuvir- and/or simeprevir-containing regimen.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)

The report entitled TreatmentTrends®: Hepatitis C Virus (US), Wave 2 also finds that the majority of surveyed physicians reported, unaided, that they are currently warehousing HCV patients in anticipation of new therapies, with nearly 30 percent of this warehousing specifically attributed to waiting for access to sofosbuvir/polymerase inhibitors. While most surveyed physicians are warehousing treatment-naive and treatment-experienced patients as they wait for the approval of simeprevir, sofosbuvir and/or other interferon-free therapy options, only 12 percent of surveyed physicians indicated they are satisfied with currently approved therapies.

"In anticipation of availability of new directly-acting antivirals, the shift in the HCV treatment paradigm is already apparent," said BioTrends Research Group Analyst Sandra Renz. "With the imminent approval of simeprevir and sofosbuvir – agents offering potentially shorter treatment duration, possible interferon-free regimens, improved safety and tolerability profiles and higher cure rates – physicians are eagerly awaiting these new regimens and holding off on prescribing treatment until they are part of the arsenal." 

The study also finds that at least one-third of surveyed physicians have received a patient request for one of the currently available HCV brands in the past month. Further, a subset of surveyed physicians has already received patient requests for sofosbuvir and simeprevir, suggesting that awareness of these products exists among patients even ahead of their anticipated U.S. launch later this year.

TreatmentTrends®: Hepatitis C Virus (US), Wave 2 is a report that covers the use of agents for the treatment of HCV infections. This biannual study focuses on current and future use of leading HCV treatment regimens, patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived value of manufacturers' patient assistance programs. In addition, this report assesses potential impact of regimens in development, including AbbVie's ABT-267, ABT-333 and ABT-450/r, Boehringer Ingelheim's faldaprevir and deleobuvir, Bristol-Myers Squibb's asunaprevir and daclatasvir, Gilead's ledipasivr and sofosbuvir and simeprevir. In the current wave of research, BioTrends surveyed 98 U.S. gastroenterologists, hepatologists and infectious disease specialists in September 2013.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Current Regulatory Expectations Affecting the Validation of Reusable Medical Devices is Subject of Dec. 4th Seminar in Boston
2. U.S. Army Rangers Initiate Groundbreaking Study on Wireless Microcurrent Generating Wound Dressing for Acute Wounds
3. Greater Efficacy on Cognition and Function Over Current Treatments Remain Neurologists Top Unmet Need in Mild to Moderate Alzheimers Disease
4. OPTIMIZERx Corporation Announces the Resignation of the Companys Current CEO & Chairman Mr. Shadron L. Stastney
5. In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic Colorectal Cancer, According to Clinical Data and Thought Leader Opinion
6. Tafinlar in Combination with Mekinist and Nivolumab Have Considerable Efficacy and Tolerability Advantages Over Currently Used Therapies for the Treatment of Unresectable Malignant Melanoma
7. For Moderate to Severe Psoriasis, Thought Leaders Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies
8. Nile Therapeutics Announces Filing of Annual and Quarterly Reports to Become Current on SEC Filings
9. Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer
10. Hepatitis C Drug Market: Forecasts for 9 Countries, Players (Current and Future) Analysis in New Research Reports
11. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology:
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
Breaking Medicine News(10 mins):